← All drugs
Drug · FAERS side-effect profile with label screen

Metoclopramide Hydrochloride side effects: what 76,703 FDA adverse event reports show

Metoclopramide Hydrochloride · 1,221 reaction terms · 361,087 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Who reports

76,703 reports · 89% serious · 9,885 with death outcome · 63% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Metoclopramide tablets are indicated for the: Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. Relief of symptoms in adults with acute and recurrent diabetic gastroparesis.

FDA label, Indications and Usage

What it is

Metoclopramide hydrochloride, USP, the active ingredient of metoclopramide tablets, USP is a dopamine-2 receptor antagonist. Metoclopramide hydrochloride (metoclopramide monohydrochloride monohydrate) is a white or practically white, crystalline, odorless or practically odorless powder.

FDA label, Description section

Boxed warning

TARDIVE DYSKINESIA Metoclopramide can cause tardive dyskinesia (TD), a serious movement disorder that is often irreversible. There is no known treatment for TD. The risk of developing TD increases with duration of treatment and total cumulative dosage [ see Warnings and Precautions ( 5.1 ) ].

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled — boxed warning 3Labeled adverse reaction 4Labeled (related wording) 3Likely indication confounding 2Reporting / coding artifact 3Not in label — unassessed 25
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,181 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Family stress1,934446.1
415.0–479.6ROR 457.6 · calibrated p 1e-13 ✓
168.1 EB05 161.9 · IC025 +7.3
3/3 methods agree
Not in label — unassessedserious n=1,934no trial arm names this drug
Tardive dyskinesia (persistent involuntary movements)16,218366.3
358.2–374.7ROR 464.3 · calibrated p 1e-13 ✓
155.6 EB05 153.6 · IC025 +7.2
3/3 methods agree
Labeled — boxed warning
exact term
serious PRR 115.7 · 79% consumerno trial arm names this drug
Lymphoid tissue hypoplasia84358.3
258.5–496.7ROR 358.7 · calibrated p 6e-12 ✓
149.0 EB05 124.1 · IC025 +6.0
3/3 methods agree
Not in label — unassessedserious n=84 · ♀ 0% (drug 63%)no trial arm names this drug
Extrapyramidal disorder12,922293.5
286.5–300.6ROR 352.7 · calibrated p 2e-12 ✓
140.8 EB05 138.7 · IC025 +7.1
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
age-adj. PRR 9.3 · serious PRR 97.3 · 71% consumerno trial arm names this drug
Thymus hypoplasia85268.7
199.0–363.0ROR 269.0 · calibrated p 7e-11 ✓
131.0 EB05 109.2 · IC025 +5.9
3/3 methods agree
Not in label — unassessedserious n=85 · ♀ 0% (drug 63%)no trial arm names this drug
Dystonia7,115158.1
153.7–162.7ROR 174.2 · calibrated p 1e-9 ✓
99.9 EB05 98.0 · IC025 +6.6
3/3 methods agree
Not in label — unassessedserious PRR 69.7no trial arm names this drug
Multiple injuries2,243148.8
141.4–156.6ROR 153.3 · calibrated p 4e-9 ✓
96.1 EB05 92.8 · IC025 +6.5
3/3 methods agree
Not in label — unassessedserious n=2,242 · 100% consumerno trial arm names this drug
Grimacing233117.0
100.4–136.5ROR 117.4 · calibrated p 4e-8 ✓
81.3 EB05 72.9 · IC025 +5.9
3/3 methods agree
Labeled adverse reaction
exact term
serious n=230no trial arm names this drug
Vaginal flatulence8096.8
75.0–125.0ROR 96.9 · calibrated p 2e-7 ✓
70.3 EB05 58.3 · IC025 +5.3
3/3 methods agree
Not in label — unassessedserious n=80 · ♀ 100% (drug 63%)no trial arm names this drug
Deformity2,42195.3
91.0–99.7ROR 98.3 · calibrated p 1e-7 ✓
70.6 EB05 68.2 · IC025 +6.1
3/3 methods agree
Not in label — unassessedserious PRR 52.0 · 100% consumerno trial arm names this drug
Economic problem3,96194.6
91.3–98.0ROR 99.7 · calibrated p 1e-7 ✓
70.2 EB05 68.4 · IC025 +6.1
3/3 methods agree
Reporting / coding artifactserious PRR 48.9 · 80% consumerno trial arm names this drug
Nervous system disorder7,52686.5
84.4–88.7ROR 95.8 · calibrated p 2e-7 ✓
65.7 EB05 64.4 · IC025 +6.0
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.7 · serious PRR 47.2 · 71% consumerno trial arm names this drug
Neovascularisation5879.9
59.6–107.1ROR 80.0 · calibrated p 1e-6 ✓
60.7 EB05 48.7 · IC025 +4.9
3/3 methods agree
Not in label — unassessedserious n=58 · ♀ 100% (drug 63%) · 100% clinicianno trial arm names this drug
Excessive eye blinking29066.7
58.6–75.8ROR 66.9 · calibrated p 2e-6 ✓
53.4 EB05 48.5 · IC025 +5.4
3/3 methods agree
Not in label — unassessedserious n=288 · 100% clinicianno trial arm names this drug
Disseminated aspergillosis7955.3
43.4–70.4ROR 55.3 · calibrated p 9e-6 ✓
45.6 EB05 37.7 · IC025 +4.8
3/3 methods agree
Not in label — unassessedserious n=79 · ♀ 0% (drug 63%)no trial arm names this drug
Quality of life decreased2,08550.1
47.9–52.5ROR 51.5 · calibrated p 1e-5 ✓
42.4 EB05 40.9 · IC025 +5.3
3/3 methods agree
Not in label — unassessedserious PRR 33.6 · 100% consumerno trial arm names this drug
Parkinson's disease39649.5
44.5–55.1ROR 49.8 · calibrated p 1e-5 ✓
41.9 EB05 38.5 · IC025 +5.2
3/3 methods agree
Not in label — unassessedserious n=369 · 100% consumerno trial arm names this drug
Activities of daily living impaired2,93246.6
44.9–48.5ROR 48.5 · calibrated p 2e-5 ✓
39.9 EB05 38.7 · IC025 +5.2
3/3 methods agree
Not in label — unassessedserious PRR 34.4no trial arm names this drug
Chorea24444.8
39.1–51.3ROR 44.9 · calibrated p 3e-5 ✓
38.4 EB05 34.5 · IC025 +4.9
3/3 methods agree
Not in label — unassessedserious n=233 · 100% consumerno trial arm names this drug
Akathisia (inner restlessness)1,89844.1
42.0–46.2ROR 45.2 · calibrated p 3e-5 ✓
38.0 EB05 36.6 · IC025 +5.2
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 33.7no trial arm names this drug
Diabetic gastroparesis5144.1
32.8–59.3ROR 44.1 · calibrated p 4e-5 ✓
37.5 EB05 29.6 · IC025 +4.3
3/3 methods agree
Likely indication confounding
term in indications
serious n=48no trial arm names this drug
Incorrect drug administration duration3,71040.8
39.4–42.2ROR 42.8 · calibrated p 3e-5 ✓
35.5 EB05 34.6 · IC025 +5.1
3/3 methods agree
Reporting / coding artifactage-adj. PRR 0.7 · serious PRR 59.2 · 100% consumerno trial arm names this drug
Computerised tomogram thorax abnormal7331.9
25.0–40.7ROR 31.9 · calibrated p 2e-4 ✓
28.4 EB05 23.4 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=73 · ♀ 100% (drug 63%) · 100% clinicianno trial arm names this drug
Movement disorder3,27330.8
29.7–31.9ROR 32.1 · calibrated p 2e-4 ✓
27.7 EB05 26.9 · IC025 +4.7
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 1.4 · serious PRR 22.5 · 70% consumerno trial arm names this drug
Stereotypy8025.4
20.2–32.0ROR 25.5 · calibrated p 7e-4 ✓
23.2 EB05 19.3 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=77no trial arm names this drug
Multiple drug therapy5824.7
18.9–32.3ROR 24.7 · calibrated p 9e-4 ✓
22.6 EB05 18.1 · IC025 +3.8
3/3 methods agree
Reporting / coding artifactserious n=58 · ♀ 100% (drug 63%) · 100% clinicianno trial arm names this drug
Dyskinesia (involuntary movements)3,22123.5
22.7–24.4ROR 24.5 · calibrated p 7e-4 ✓
21.7 EB05 21.1 · IC025 +4.4
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 3.7 · serious PRR 18.2no trial arm names this drug
Partner stress7623.3
18.4–29.4ROR 23.3 · calibrated p 0.001 ✓
21.4 EB05 17.6 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=75no trial arm names this drug
Anhedonia1,79819.8
18.9–20.8ROR 20.3 · calibrated p 0.002 ✓
18.6 EB05 17.8 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious PRR 13.2no trial arm names this drug
Fear1,79419.3
18.4–20.3ROR 19.8 · calibrated p 0.002 ✓
18.1 EB05 17.4 · IC025 +4.1
3/3 methods agree
Not in label — unassessedage-adj. PRR 2.1 · serious PRR 15.7no trial arm names this drug
Parkinsonism61418.3
16.9–19.9ROR 18.5 · calibrated p 0.003 ✓
17.2 EB05 16.1 · IC025 +4.0
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 12.1no trial arm names this drug
Metabolic disorder35918.0
16.1–20.0ROR 18.0 · calibrated p 0.003 ✓
16.9 EB05 15.5 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=335no trial arm names this drug
Nephrogenic anaemia28918.0
15.9–20.2ROR 18.0 · calibrated p 0.003 ✓
16.9 EB05 15.3 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious n=289no trial arm names this drug
Hyperparathyroidism secondary14917.0
14.4–20.1ROR 17.1 · calibrated p 0.004 ✓
16.0 EB05 14.0 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious n=149no trial arm names this drug
Chronic kidney disease-mineral and bone disorder6316.9
13.1–21.9ROR 17.0 · calibrated p 0.005 ✓
15.9 EB05 12.8 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious n=63no trial arm names this drug
Female genital tract fistula9916.6
13.6–20.4ROR 16.6 · calibrated p 0.005 ✓
15.7 EB05 13.2 · IC025 +3.5
3/3 methods agree
Not in label — unassessedserious n=98 · ♀ 100% (drug 63%)no trial arm names this drug
Neutropenic sepsis37615.1
13.6–16.8ROR 15.2 · calibrated p 0.007 ✓
14.3 EB05 13.2 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious PRR 9.2 · 94% clinicianno trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Extrapyramidal19,03660.259.4–61.1signal
Neutropenia / agranulocytosis3,8974.44.2–4.5signal
Hyponatraemia1,0843.73.5–3.9signal
Anaemia2,9692.72.6–2.8signal
Kidney injury4,3932.62.6–2.7signal
Severe cutaneous reaction6462.42.2–2.6signal
Arrhythmia / qt1,6582.42.2–2.5signal
Thrombocytopenia1,8742.32.2–2.4signal
Pancreatitis6272.12.0–2.3raised
Gi bleeding1,3902.12.0–2.2raised
Depression1,9931.91.9–2.0raised
Serious infection5,4651.91.9–2.0raised
Venous thromboembolism1,5201.91.8–2.0raised
Interstitial lung disease6661.91.8–2.1raised
Anaphylaxis / angioedema8191.81.7–1.9raised
Liver injury1,8791.71.6–1.8raised

Trial evidence (ClinicalTrials.gov)

ClinicalTrials.gov returned results-bearing trials mentioning Metoclopramide only as a background or rescue medication (NCT02625181, NCT01636947); no trial listing it as the tested intervention was cached, so no trial cross-check is shown.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Tardive dyskinesia (persistent involuntary movements)16,218366.3
358.2–374.7ROR 464.3 · calibrated p 1e-13 ✓
155.6 EB05 153.6 · IC025 +7.2
3/3 methods agree
Labeled — boxed warning
exact term
serious PRR 115.7 · 79% consumerno trial arm names this drug
Extrapyramidal disorder12,922293.5
286.5–300.6ROR 352.7 · calibrated p 2e-12 ✓
140.8 EB05 138.7 · IC025 +7.1
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
age-adj. PRR 9.3 · serious PRR 97.3 · 71% consumerno trial arm names this drug
Nervous system disorder7,52686.5
84.4–88.7ROR 95.8 · calibrated p 2e-7 ✓
65.7 EB05 64.4 · IC025 +6.0
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.7 · serious PRR 47.2 · 71% consumerno trial arm names this drug
Dystonia7,115158.1
153.7–162.7ROR 174.2 · calibrated p 1e-9 ✓
99.9 EB05 98.0 · IC025 +6.6
3/3 methods agree
Not in label — unassessedserious PRR 69.7no trial arm names this drug
Nausea6,4952.3
2.2–2.3ROR 2.4 · calibrated p 0.867
2.3 EB05 2.2 · IC025 +1.1
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.6 · serious PRR 2.5no trial arm names this drug
Pain5,9722.7
2.6–2.7ROR 2.8 · calibrated p 0.691
2.7 EB05 2.6 · IC025 +1.4
3/3 methods agree
Not in label — unassessedage-adj. PRR 1.5 · serious PRR 2.6no trial arm names this drug
Vomiting4,9442.9
2.8–3.0ROR 3.0 · calibrated p 0.615
2.9 EB05 2.8 · IC025 +1.5
3/3 methods agree
Not in label — unassessedage-adj. PRR 3.3 · serious PRR 2.5no trial arm names this drug
Anxiety4,0994.0
3.9–4.1ROR 4.1 · calibrated p 0.353
3.9 EB05 3.8 · IC025 +1.9
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.0 · serious PRR 3.6no trial arm names this drug
Diarrhoea (diarrhea)4,0931.7
1.7–1.8ROR 1.8 · calibrated p 0.822
1.7 EB05 1.7 · IC025 +0.7Labeled adverse reaction
exact term
age-adj. PRR 2.0 · serious PRR 1.8no trial arm names this drug
Economic problem3,96194.6
91.3–98.0ROR 99.7 · calibrated p 1e-7 ✓
70.2 EB05 68.4 · IC025 +6.1
3/3 methods agree
Reporting / coding artifactserious PRR 48.9 · 80% consumerno trial arm names this drug
Incorrect drug administration duration3,71040.8
39.4–42.2ROR 42.8 · calibrated p 3e-5 ✓
35.5 EB05 34.6 · IC025 +5.1
3/3 methods agree
Reporting / coding artifactage-adj. PRR 0.7 · serious PRR 59.2 · 100% consumerno trial arm names this drug
Fatigue (tiredness)3,5321.2
1.2–1.3ROR 1.3 · calibrated p 0.478
1.2 EB05 1.2 · IC025 +0.3Labeled adverse reaction
exact term
age-adj. PRR 1.4 · serious PRR 1.3no trial arm names this drug
Movement disorder3,27330.8
29.7–31.9ROR 32.1 · calibrated p 2e-4 ✓
27.7 EB05 26.9 · IC025 +4.7
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 1.4 · serious PRR 22.5 · 70% consumerno trial arm names this drug
Dyspnoea (shortness of breath)3,2611.6
1.5–1.6ROR 1.6 · calibrated p 0.710
1.6 EB05 1.5 · IC025 +0.6Labeled adverse reaction
exact term
age-adj. PRR 1.8 · serious PRR 1.3no trial arm names this drug
Dyskinesia (involuntary movements)3,22123.5
22.7–24.4ROR 24.5 · calibrated p 7e-4 ✓
21.7 EB05 21.1 · IC025 +4.4
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 3.7 · serious PRR 18.2no trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Metoclopramide ↔ Tardive dyskinesia.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Metoclopramide?

In FDA FAERS, the most frequently co-reported reaction terms for Metoclopramide are tardive dyskinesia, extrapyramidal disorder, nervous system disorder, dystonia, nausea, pain. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Metoclopramide have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: TARDIVE DYSKINESIA Metoclopramide can cause tardive dyskinesia (TD), a serious movement disorder that is often irreversible. There is no known treatment for TD. The risk of developing TD increases with duration of treatment and total cumulative dosage [ see Warnings and Precautions ( 5.1 ) ].

Do FAERS signals prove that Metoclopramide causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.